Method of treating chronic herpes virus infections using an opiate receptor antagonist
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 18, 1994
Issued Date -
N/A
app pub date -
May 10, 1993
filing date -
Oct 7, 1986
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Chronic herpes virus infections are treated in human patients by the administration by a pharmacologically effective mode or route of an essentially pure opiate receptor antagonist, preferably an essentially pure opiate receptor antagonist exhibiting substantially higher blocking action against Mu opiate receptor sites than against Delta receptor sites, exemplified by Naltrexone and Naloxone, at a low dose concentration which produces therapeutic results corresponding to those produced by Naltrexone when administered in the range of 1 mg to 10 mg and at which Delta receptor blocking activity is at most small while Mu receptor blocking activity is significant and most preferably exclusive.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully